William Blair analyst Sami Corwin has reiterated their bullish stance on NGNE stock, giving a Buy rating on June 20.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Sami Corwin has given his Buy rating due to a combination of factors related to Neurogene’s promising advancements in their gene therapy for Rett Syndrome. The company has reached an agreement with the FDA on a pivotal trial design for NGN-401, which is a significant step forward. This trial will be a single-arm, open-label study involving patients aged 3 years and older, focusing on improvements in clinical global impressions and developmental milestones.
Neurogene’s trial design has been de-risked by positive interim Phase I data, where all patients treated with the low dose of NGN-401 showed meaningful improvements. These patients achieved notable scores on the Clinical Global Impression-Improvement scale and gained multiple developmental skills. The ongoing success and tolerability of the low dose, along with the potential for further skill acquisition over time, reinforce the positive outlook for Neurogene’s stock.
In another report released on June 20, Craig-Hallum also initiated coverage with a Buy rating on the stock with a $50.00 price target.